Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus radiotherapy followed by durvalumab as preoperative treatment for rectal cancer
2018-004758-39Phase 2Completed
- Sponsor
- AUSL Romagna
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in rectal adenocarcinoma and rectal cancer, sponsored by AUSL Romagna. Primary endpoint: Pathological complete response rate. Started Jun 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2018-004758-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004758-39.